Qualitative study into quality of life issues surrounding insulin pump use in type 1 diabetes

Practical Diabetes International

Volumn 24, Issue 3, 2007, Pages 143-148

  Barnard, Katharine D ^a,b   Skinner, T Chas ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Continuous subcutaneous insulin infusion; CSII; Health outcome; Health status; Insulin pump; Quality of life; Well being

Indexed keywords

INSULIN;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG DELIVERY SYSTEM; FAMILY; FREEDOM; HEALTH CARE POLICY; HUMAN; INDEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTERVIEW; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITATIVE RESEARCH; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; WELLBEING;

EID: 35648958801     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1079     Document Type: Article

References (13)

1. Rodrigues IAS, Reid K, Ismail K, et al. Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service. Diabetic Med 2005; 22: 842-849.
2. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Med 2002; 19: 746-751.
3. Chantelau E, Schiffers T, Schutze J, et al. Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns 1997; 30(2): 167-173.
4. Bruttomesso D, Pianta A, Crazzolara D, et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabetic Med 2002; 19: 628-634.
5. Hoogma RPLM, Spijker AJM, van Doorn-Scheele M, et al. Quality of life and metabolic control in patients with diabetes mellitus type I treated by continuous subcutaneous insulin infusion or multiple daily insulin injections. Neth J Med 2004; 62 (10): 383-487.
6. Kamoi K, Miyakoshi M, Maruyama E. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004: 64: 19-25.
7. Tsui E, Barnie A, Ross S, et al. Intensive Insulin Therapy with Insulin Lispro: a randomised trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001; 24(10): 1722-1727.
8. Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Paediatrics 2003; 112: 559-564.
9. Diabetes Quality of Life Measure, appended to: Jacobson A, Barofsky I, Cleary P, et al. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). Diabetes Care 1988; 11(9): 725-732.
10. [No authors listed.] Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Paediatrics 1994; 125: 177-188
11. Cox D, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
12. Speight J. Development of knowledge and quality of life measures for improving diabetes care. PhD Thesis, held at Senate House, University of London, 2003.
13. Barnard, KD, Lloyd, CE, Skinner, TC. Systematic Literature Review into Quality of Life Issues Associated with Insulin Pump Use in Type 1 Diabetes. Diabetic Med (in press).